The effect of nitroglycerin infusion versus hydralazine infusion as antihypertensive therapy in acute management of patients with severe pre-eclampsia

Ali, Rania M; Salah, Dina; Mansour, Dina Yahia

doi:10.4103/1687-7934.172670

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 320 articles were retrieved, of which 51 were included in the systematic review and 46 in the meta‐analysis. The PRISMA flow chart is depicted in Figure .…”

Section: Resultsmentioning

confidence: 99%

Drugs for treating severe hypertension in pregnancy: a network meta‐analysis and trial sequential analysis of randomized clinical trials

Sridharan

Sequeira

2018

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…A total of 320 articles were retrieved, of which 51 were included in the systematic review and 46 in the meta‐analysis. The PRISMA flow chart is depicted in Figure .…”

Section: Resultsmentioning

confidence: 99%

Drugs for treating severe hypertension in pregnancy: a network meta‐analysis and trial sequential analysis of randomized clinical trials

Sridharan

Sequeira

2018

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…GTN is an organic nitrate that has been demonstrated to significantly reduce maternal blood pressure and umbilical artery resistance, without affecting uterine artery resistance in a pilot clinical trial of 12 women with severe preeclampsia . Many other clinical trials assessing the potential for GTN as an anti‐hypertensive treatment for preeclampsia report a reduction in blood pressure . These studies also report a side effect of severe headaches from nitrate.…”

Section: No Pathwaymentioning

confidence: 99%

Targeting the vascular dysfunction: Potential treatments for preeclampsia

et al. 2019

View full text Add to dashboard Cite

Preeclampsia is a pregnancy-specific disorder clinically characterized by new-onset hypertension (>20 weeks' gestation) with one or more of proteinuria and maternal organ dysfunction such as renal insufficiency, liver dysfunction, neurological complications, fetal growth restriction, or uteroplacental dysfunction. 1,2 Each year, preeclampsia is the principal cause of death in over 60 000 women and in more than 500 000 babies globally. 3 The pathophysiological mechanisms underlying the disease are still not entirely clear. Briefly, In 2017, Sarah was awarded her PhD at the University of Melbourne, Australia, and is currently an NHMRC Peter Doherty Research Fellow in the Department of Obstetrics and Gynecology at Monash University, Australia. The focus of her research is to assess the potential of new and old therapeutics to target the vascular dysfunction of preeclampsia, and translate these studies into clinical application. AbstractPreeclampsia is a pregnancy-specific disorder, primarily characterized by new-onset hypertension in combination with a variety of other maternal or fetal signs. The pathophysiological mechanisms underlying the disease are still not entirely clear.Systemic maternal vascular dysfunction underlies the clinical features of preeclampsia. It is a result of oxidative stress and the actions of excessive anti-angiogenic factors, such as soluble fms-like tyrosine kinase, soluble endoglin, and activin A, released by a dysfunctional placenta. The vascular dysfunction then leads to impaired regulation and secretion of relaxation factors and an increase in sensitivity/production of constrictors. This results in a more constricted vasculature rather than the relaxed vasodilated state associated with normal pregnancy. Currently, the only effective "treatment" for preeclampsia is delivery of the placenta and therefore the baby.Often, this means a preterm delivery to save the life of the mother, with all the attendant risks and burdens associated with fetal prematurity. To lessen this burden, there is a pressing need for more effective treatments that target the maternal vascular dysfunction that underlies the hypertension. This review details the vascular effects of key drugs undergoing clinical assessment as potential treatments for women with preeclampsia.

show abstract

Nitroglycerin versus labetalol to control the blood pressure in acute severe pre-eclampsia

Ali

Salah

2022

Egyptian Journal of Anaesthesia

View full text Add to dashboard Cite

The effect of nitroglycerin infusion versus hydralazine infusion as antihypertensive therapy in acute management of patients with severe pre-eclampsia

Cited by 3 publications

References 0 publications

Drugs for treating severe hypertension in pregnancy: a network meta‐analysis and trial sequential analysis of randomized clinical trials

Drugs for treating severe hypertension in pregnancy: a network meta‐analysis and trial sequential analysis of randomized clinical trials

Targeting the vascular dysfunction: Potential treatments for preeclampsia

Nitroglycerin versus labetalol to control the blood pressure in acute severe pre-eclampsia

Contact Info

Product

Resources

About